The AHA Friday urged the National Academies of Sciences, Engineering and Medicine to adopt a unified set of guidelines to account for the variables associated with all issues of the eventual allocation of COVID-19 vaccine allocation.

In an effort to ensure the process remains equitable, AHA stressed the importance of a singular message to the public and other stakeholders.

“The country has been confused by the multiple and sometimes conflicting information on testing, infection prevention, return-to-work and school and many other decision points as we move through this pandemic,” AHA wrote. “We recognize that science is evolving, but in this extremely important consideration of achieving immunity, we cannot further the uncertainty of individuals, providers or public health officials.”

Read AHA’s full comments, which also address vaccine hesitancy, the potential for multiple available vaccines, comorbidity considerations and public- and private-sector decisions and policies.

Related News Articles

Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…